Co-careldopa 10mg/100mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
20 branded products available
Part of the Sinemet brand family (generic: Co-careldopa)
MHRA licensed products
View all licensed products for Co-careldopa on the MHRA register
Sinemet 10mg/100mg tablets
Sinemet 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
Co-careldopa 10mg/100mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
600 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 30 · Randomised trials: 13 · 1984–2026
Showing the 50 most relevant studies, sorted by most relevant.
Stefanie T. Jost, Marie‐Ann Kaldenbach, Angelo Antonini, et al.
Movement Disorders, 2023
- Levodopa
- Parkinson Disease
- Antiparkinson Agents
Claire L Tomlinson, Rebecca Stowe, Smitaa Patel, et al.
Movement Disorders, 2010
- Antiparkinson Agents
- Levodopa
- Parkinson Disease
J. Ahlskog, M. Muenter
Movement Disorders, 2001
- Antiparkinson Agents
- Australia
- Canada
Constant V.M. Verschuur, Sven R. Suwijn, Judith A. Boel, et al.
New England Journal of Medicine, 2019
- Antiparkinson Agents
- Carbidopa
- Levodopa
A. Schapira, S. Fox, R. Hauser, et al.
JAMA Neurology, 2017
Karin Wirdefeldt, Per Odin, Dag Nyholm
CNS Drugs, 2016
- Quality of Life
- Antiparkinson Agents
- Carbidopa
W. Oertel, K. Eggert, R. Pahwa, et al.
Movement Disorders, 2017
Robert A. Hauser, Ann Hsu, Sherron Kell, et al.
The Lancet Neurology, 2013
- Carbidopa
- Chemistry, Pharmaceutical
- Delayed-Action Preparations
R. Holloway, I. Shoulson, K. Kieburtz, et al.
JAMA, 2000
- Pramipexole
- Antiparkinson Agents
- Carrier Proteins
R. Holloway, I. Shoulson, S. Fahn, et al.
Archives of neurology, 2004
- Pramipexole
- Levodopa
- Parkinson Disease
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.